Patients with bipolar disorder (BD), schizophrenia, or other psychotic disorders who reported synthetic cannabinoid use at admission to the hospital had shorter length of stay (LOS) and received lower doses of antipsychotics, irrespective of clinical diagnoses, a recent study found. Synthetic cannabinoid products have become popular and have led to an increased number of patients presenting to emergency departments and psychiatric hospitals. The purpose of this study was to evaluate the impact of synthetic cannabinoid use at admission on LOS and doses of antipsychotics at discharge in individuals with BD, schizophrenia, and other psychotic disorders. Researchers retrospectively examined medical records of 324 inpatients admitted from January 2014 to July 2015. They found:
- Synthetic cannabinoid use predicted LOS and antipsychotic dose using structural equation modeling.
- Further, the association of synthetic cannabinoid use with LOS was partly mediated by antipsychotic dose.
- These associations were independent of specific diagnosis.
Deng H, Mohite S, Suchting R, Nielsen DA, Okusaga OO. Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disorders. [Published online ahead of print January 3, 2018]. Psychiatry Res. doi:10.1016/j.psychres.2017.12.089.
This Week's Must Reads
Is Viewing Sexually Explicit Material Cheating?, Arch Sex Behav; 2018 Apr; Negy, Plaza, et al
Breast Cancer Incidence Higher in Schizophrenia, JAMA Psychiatry; ePub 2018 Mar 7; Zhuo, et al
Sleep, Trauma, and Psychosis-Like Experiences, Schizophr Res; ePub 2018 Mar 8; Andorko, et al
Patient Characteristics Indicate Treatment Options, Depress Anxiety; ePub 2018 Feb 28; Keefe, et al
Trajectories of Depressive Symptoms Among Nurses, J Affect Disord; ePub 2018 Feb 27; Duan-Porter, et al
Must Reads in Bipolar Disorder
BP Disorder Linked with Higher Triglyceride Levels, Bipolar Disord; ePub 2018 Feb 26; Wulsin, et al
Olfactory Processing in Mood Disorders Examined, Bipolar Disord; ePub 2018 Feb 13; Kamath, et al
Axis II Comorbidities in BD: Mood State Matters, Bipolar Disord; ePub 2018 Jan 25; Post, et al
Synthetic Cannabinoid, Psychotic Disorders, and LOS, Psychiatry Res; ePub 2018 Jan 3; Deng, Mohite, et al
FDA Approves First US Digital Medicine System, FDA news release; 2017 Nov 14